A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL
Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials.
Share
Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
'We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way.
'This important milestone represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,' commented Erik Lazarich, A.forall's President of U.S. Operations.
Please see link for Full Prescribing Information.
About A.forall & Milla Pharmaceuticals
At A.forall, our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world.
Milla Pharmaceuticals Inc., the U.S. subsidiary of A.forall, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
IFF Declares Dividend for Third Quarter 2025
NEW YORK, July 30, 2025--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 10, 2025 to shareholders of record as of September 29, 2025. Welcome to IFFAt IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on Contacts Media Relations:Paulina Investor Relations:Michael Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 minutes ago
- Business Wire
New Research Illustrates Gaps in COPD Care and the Need for Better Patient-Provider Communication
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Patients with chronic obstructive pulmonary disease (COPD) face significant challenges, but conversations with healthcare providers can play a critical role in helping patients understand their condition, set realistic goals, ease symptom burden and improve their quality of life, according to new research from the COPD Foundation and Phreesia. COPD is a chronic and progressive lung disease that affects more than 16 million people in the United States and is the sixth leading cause of death. The study, published in Chronic Obstructive Pulmonary Diseases: The Journal of the COPD Foundation, with funding support from Verona Pharma, was based on voluntary surveys from 1,615 COPD patients in January 2025. Patients completed the survey on Phreesia's platform after checking in for their doctor appointments and providing consent. Patients reported significant symptom burden, with 43% of patients saying they experience COPD symptoms, including shortness of breath and fatigue, at least 24 days in a typical month and a quarter of patients reporting symptoms every day. Patients also reported significant impacts to their quality of life, with around two-thirds saying COPD had a moderate-to-great impact on their daily lives and half reporting a moderate-to-great impact on their emotional health. COPD also impacted patients' ability to work, with 15% saying they had lost a job due to their condition. Surveyed patients also reported barriers to medication. One in five patients reported not using any maintenance medications. Among those patients, 27% said they didn't think their COPD was severe enough and 27% said their provider had not recommended maintenance therapy. Seventy-one percent of patients who had not tried any COPD medications said they would be likely to try them. And among patients who had tried maintenance medications, 80% said it was because their doctor had recommended it. Despite this opportunity for patient-provider discussions around maintenance medications and other treatment options, the study found significant communication gaps between patients and their healthcare providers. Only 45% of patients reported having detailed discussions about their COPD symptoms with their providers, and 22% of patients said they provided little to no symptom detail during visits. Additionally, more than a third of patients reported having limited to no understanding of COPD. That percentage was even higher among Black patients and patients aged 45−64 years, 46% and 41% respectively, highlighting the potential for targeted interventions. 'These findings point to the urgent need to improve communication between patients and their providers and ensure conversations are as engaging, informative and productive as possible,' said David Mannino, MD, Co-Founder and Medical Director of the COPD Foundation and the study's lead author. 'Equipping patients with the right information and resources can help them take a more active role in their care and improve health outcomes.' 'Given what we know about the benefits of giving patients relevant, credible health information at the point of care, these results have important implications that can be used to support patients struggling with COPD,' said David Linetsky, Phreesia's President, Network Solutions. 'At Phreesia, we've seen firsthand that when patients have more meaningful conversations with their providers, it helps them manage their treatment and improves quality of life.' For more information on Phreesia, visit Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit
Business Wire
3 minutes ago
- Business Wire
Travere Therapeutics to Report Second Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Travere Therapeutics to report second quarter 2025 financial results on August 6, 2025, after the close of the U.S. financial markets. Share The webcast and dial-in information can be accessed on the Investor page of Travere's website at Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit
